Literature DB >> 9713625

Reversible cardiomyopathy in a patient with hairy cell leukaemia.

G T Sucak1, R Haznedar, R Yalçin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9713625      PMCID： PMC2360904          DOI： 10.1136/pgmj.74.871.313

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  6 in total

1.  Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma.

Authors:  L R Deyton; R E Walker; J A Kovacs; B Herpin; M Parker; H Masur; A S Fauci; H C Lane
Journal:  N Engl J Med       Date:  1989-11-02       Impact factor: 91.245

2.  Reversible cardiomyopathy induced by interferon.

Authors:  M Sonnenblick; D Rosenmann; A Rosin
Journal:  BMJ       Date:  1990-05-05

3.  Recombinant alpha 2 interferon-related cardiomyopathy.

Authors:  M C Cohen; M S Huberman; R W Nesto
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

Review 4.  Cardiotoxicity of interferon. A review of 44 cases.

Authors:  M Sonnenblick; A Rosin
Journal:  Chest       Date:  1991-03       Impact factor: 9.410

5.  Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients.

Authors:  G J Jones; L M Itri
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

6.  Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication.

Authors:  W H Kruit; K J Punt; S H Goey; P H de Mulder; D C van Hoogenhuyze; S C Henzen-Logmans; G Stoter
Journal:  Cancer       Date:  1994-11-15       Impact factor: 6.860
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.